Disparities in lung cancer survival and receipt of surgical treatment

Chima A. Osuoha, Karen E. Callahan, Carmen P. Ponce, Paulo Pinheiro

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Lung cancer accounts for the greatest proportion of cancer deaths in the United States. This study aims to characterize lung cancer survival by racial/ethnic group and ascertain any modifiable determinants of identified disparities in the newly diverse Mountain West by using the state of Nevada. Materials and methods: 12,964 first primary lung cancer cases diagnosed between 2003 and 2010 were identified for analysis from the Nevada Central Cancer Registry and followed for vital status until December 31, 2011. Standardized age-adjusted five-year survival stratified by race/ethnicity was computed using life table methods. Hazard ratios adjusted for covariates were estimated using Cox proportional hazards regression modeling. Adjusted odds of receiving surgical treatment for localized non-small cell lung cancer by region of Nevada were compared using logistic regression. Results: By the end of the follow-up period, 86% of lung cancer cases in Nevada were deceased. Five-year overall survival was 12.3% (95%CI: 11.5–13.1) for males and 18.9% (95%CI: 17.9–19.9) for females. Compared to cases in Northwestern Nevada, patients in Southern and Rural Nevada had 9% (HR:1.09; 95% CI:1.04–1.14) and 10% (HR:1.10; 95% CI:1.02–1.19) higher risk of dying from lung cancer, respectively. For localized non-small cell lung cancer (NSCLC), which is potentially curable, Southern Nevadans had 67% higher odds of not receiving surgical treatment than Northwestern Nevadans (OR 1.67; 95%CI: 1.30–2.13). Conclusions: While the prognosis for lung cancer survival in Nevada is poor for all populations, there is no racial/ethnic disparity. However, there is a considerable survival disparity by geographic region, with Southern Nevadans disproportionately impacted. Potential modifiable factors include treatment differences, particularly in receipt of surgery for potentially curative tumor types such as localized NSCLC. Further studies are required to identify barriers to receipt of surgery in Southern Nevada.

Original languageEnglish (US)
Pages (from-to)54-59
Number of pages6
JournalLung Cancer
Volume122
DOIs
StatePublished - Aug 1 2018

Fingerprint

Lung Neoplasms
Survival
Non-Small Cell Lung Carcinoma
Therapeutics
Neoplasms
Life Tables
Ethnic Groups
Registries
Logistic Models
Population

Keywords

  • Disparity
  • Lung cancer
  • Nevada
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Disparities in lung cancer survival and receipt of surgical treatment. / Osuoha, Chima A.; Callahan, Karen E.; Ponce, Carmen P.; Pinheiro, Paulo.

In: Lung Cancer, Vol. 122, 01.08.2018, p. 54-59.

Research output: Contribution to journalArticle

Osuoha, Chima A. ; Callahan, Karen E. ; Ponce, Carmen P. ; Pinheiro, Paulo. / Disparities in lung cancer survival and receipt of surgical treatment. In: Lung Cancer. 2018 ; Vol. 122. pp. 54-59.
@article{2726f5ea65544dca8dea7326c58ec6dc,
title = "Disparities in lung cancer survival and receipt of surgical treatment",
abstract = "Background: Lung cancer accounts for the greatest proportion of cancer deaths in the United States. This study aims to characterize lung cancer survival by racial/ethnic group and ascertain any modifiable determinants of identified disparities in the newly diverse Mountain West by using the state of Nevada. Materials and methods: 12,964 first primary lung cancer cases diagnosed between 2003 and 2010 were identified for analysis from the Nevada Central Cancer Registry and followed for vital status until December 31, 2011. Standardized age-adjusted five-year survival stratified by race/ethnicity was computed using life table methods. Hazard ratios adjusted for covariates were estimated using Cox proportional hazards regression modeling. Adjusted odds of receiving surgical treatment for localized non-small cell lung cancer by region of Nevada were compared using logistic regression. Results: By the end of the follow-up period, 86{\%} of lung cancer cases in Nevada were deceased. Five-year overall survival was 12.3{\%} (95{\%}CI: 11.5–13.1) for males and 18.9{\%} (95{\%}CI: 17.9–19.9) for females. Compared to cases in Northwestern Nevada, patients in Southern and Rural Nevada had 9{\%} (HR:1.09; 95{\%} CI:1.04–1.14) and 10{\%} (HR:1.10; 95{\%} CI:1.02–1.19) higher risk of dying from lung cancer, respectively. For localized non-small cell lung cancer (NSCLC), which is potentially curable, Southern Nevadans had 67{\%} higher odds of not receiving surgical treatment than Northwestern Nevadans (OR 1.67; 95{\%}CI: 1.30–2.13). Conclusions: While the prognosis for lung cancer survival in Nevada is poor for all populations, there is no racial/ethnic disparity. However, there is a considerable survival disparity by geographic region, with Southern Nevadans disproportionately impacted. Potential modifiable factors include treatment differences, particularly in receipt of surgery for potentially curative tumor types such as localized NSCLC. Further studies are required to identify barriers to receipt of surgery in Southern Nevada.",
keywords = "Disparity, Lung cancer, Nevada, Surgery, Survival",
author = "Osuoha, {Chima A.} and Callahan, {Karen E.} and Ponce, {Carmen P.} and Paulo Pinheiro",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.lungcan.2018.05.022",
language = "English (US)",
volume = "122",
pages = "54--59",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Disparities in lung cancer survival and receipt of surgical treatment

AU - Osuoha, Chima A.

AU - Callahan, Karen E.

AU - Ponce, Carmen P.

AU - Pinheiro, Paulo

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background: Lung cancer accounts for the greatest proportion of cancer deaths in the United States. This study aims to characterize lung cancer survival by racial/ethnic group and ascertain any modifiable determinants of identified disparities in the newly diverse Mountain West by using the state of Nevada. Materials and methods: 12,964 first primary lung cancer cases diagnosed between 2003 and 2010 were identified for analysis from the Nevada Central Cancer Registry and followed for vital status until December 31, 2011. Standardized age-adjusted five-year survival stratified by race/ethnicity was computed using life table methods. Hazard ratios adjusted for covariates were estimated using Cox proportional hazards regression modeling. Adjusted odds of receiving surgical treatment for localized non-small cell lung cancer by region of Nevada were compared using logistic regression. Results: By the end of the follow-up period, 86% of lung cancer cases in Nevada were deceased. Five-year overall survival was 12.3% (95%CI: 11.5–13.1) for males and 18.9% (95%CI: 17.9–19.9) for females. Compared to cases in Northwestern Nevada, patients in Southern and Rural Nevada had 9% (HR:1.09; 95% CI:1.04–1.14) and 10% (HR:1.10; 95% CI:1.02–1.19) higher risk of dying from lung cancer, respectively. For localized non-small cell lung cancer (NSCLC), which is potentially curable, Southern Nevadans had 67% higher odds of not receiving surgical treatment than Northwestern Nevadans (OR 1.67; 95%CI: 1.30–2.13). Conclusions: While the prognosis for lung cancer survival in Nevada is poor for all populations, there is no racial/ethnic disparity. However, there is a considerable survival disparity by geographic region, with Southern Nevadans disproportionately impacted. Potential modifiable factors include treatment differences, particularly in receipt of surgery for potentially curative tumor types such as localized NSCLC. Further studies are required to identify barriers to receipt of surgery in Southern Nevada.

AB - Background: Lung cancer accounts for the greatest proportion of cancer deaths in the United States. This study aims to characterize lung cancer survival by racial/ethnic group and ascertain any modifiable determinants of identified disparities in the newly diverse Mountain West by using the state of Nevada. Materials and methods: 12,964 first primary lung cancer cases diagnosed between 2003 and 2010 were identified for analysis from the Nevada Central Cancer Registry and followed for vital status until December 31, 2011. Standardized age-adjusted five-year survival stratified by race/ethnicity was computed using life table methods. Hazard ratios adjusted for covariates were estimated using Cox proportional hazards regression modeling. Adjusted odds of receiving surgical treatment for localized non-small cell lung cancer by region of Nevada were compared using logistic regression. Results: By the end of the follow-up period, 86% of lung cancer cases in Nevada were deceased. Five-year overall survival was 12.3% (95%CI: 11.5–13.1) for males and 18.9% (95%CI: 17.9–19.9) for females. Compared to cases in Northwestern Nevada, patients in Southern and Rural Nevada had 9% (HR:1.09; 95% CI:1.04–1.14) and 10% (HR:1.10; 95% CI:1.02–1.19) higher risk of dying from lung cancer, respectively. For localized non-small cell lung cancer (NSCLC), which is potentially curable, Southern Nevadans had 67% higher odds of not receiving surgical treatment than Northwestern Nevadans (OR 1.67; 95%CI: 1.30–2.13). Conclusions: While the prognosis for lung cancer survival in Nevada is poor for all populations, there is no racial/ethnic disparity. However, there is a considerable survival disparity by geographic region, with Southern Nevadans disproportionately impacted. Potential modifiable factors include treatment differences, particularly in receipt of surgery for potentially curative tumor types such as localized NSCLC. Further studies are required to identify barriers to receipt of surgery in Southern Nevada.

KW - Disparity

KW - Lung cancer

KW - Nevada

KW - Surgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85047425530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047425530&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2018.05.022

DO - 10.1016/j.lungcan.2018.05.022

M3 - Article

VL - 122

SP - 54

EP - 59

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -